The next generation RNA therapeutics market presents significant growth opportunities, driven by the development of over 100 RNA therapies and vaccines, advancing research, and robust investment ...

COVID-19 is still circulating and there are fears that further spikes in cases are to be expected in the coming months. Ben Hargreaves highlights the innovation in vaccine delivery that could make a ...

A study published in the Journal of Veterinary Pharmacology and Therapeutics on Feb. 7, 2026, has quantified the amount of ...

Proper pullet vaccination underpins the protection of layers and broiler breeders during the rearing phase. When done correctly, it stabilises egg ...

Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...

There might be a growing buzz around testosterone replacement therapy but that doesn't mean it's just a lifestyle trend.

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers ...

ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, ...

Three experimental injectable antiretrovirals – a novel capsid inhibitor and two next-generation integrase inhibitors – could ...

Explore the future of gene therapy delivery with lipid nanoparticles. Learn how they can transform treatments for various diseases.

Discover how scientists are unlocking the potential of a natural compound, Anemoside B4, to fight inflammation and immune disorders. From its unique discovery process to promising applications in both ...

Xeris Biopharma benefits from the FDA's CRL to Corcept's relacorilant, removing a major competitive threat to Recorlev sales ...